In Dublin, the global market for pharmaceutical safety assessment is on the rise, with a notable increase from $10.47 billion in 2024 to an estimated $11.32 billion in 2025. This growth showcases a Compound Annual Growth Rate (CAGR) of 8.1%. Factors contributing to this expansion include a surge in preclinical research demands, more stringent drug safety protocols, rising reliance on contract research organizations, and advancements in the field.